Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -2.31% | -53.99% |
Business Summary
Number of employees: 13
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Cellular Immunotherapies
100.0
%
| 6 | 100.0 % | 2 | 100.0 % | -75.81% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 6 | 100.0 % | 2 | 100.0 % | -75.81% |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 11,901,026 | 11,716,439 ( 98.45 %) | 67,746 ( 0.5692 %) | 98.45 % |
Stock B | 0 | 452,000 | 0 | 0 |
Company contact information
Bellicum Pharmaceuticals, Inc.
3730 Kirby Drive Suite 1200
77098, Houston
+281 454 3424
http://www.bellicum.comSector
1st Jan change | Capi. | |
---|---|---|
-53.99% | 822K | |
+10.79% | 116B | |
+11.65% | 106B | |
-6.20% | 23.89B | |
-3.00% | 21.58B | |
-10.88% | 18.96B | |
-13.41% | 16.33B | |
-40.50% | 16.96B | |
+6.64% | 14.14B | |
+31.84% | 12.02B |
- Stock Market
- Equities
- BPXA Stock
- Company Bellicum Pharmaceuticals, Inc.